Actively Recruiting
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-02-09
181
Participants Needed
1
Research Sites
626 weeks
Total Duration
On this page
Sponsors
M
Memorial Sloan Kettering Cancer Center
Lead Sponsor
W
Weill Medical College of Cornell University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.
CONDITIONS
Official Title
Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years or older undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, or duodenal ampullectomy for presumed ductal adenocarcinoma, IPMN, pancreatic neuroendocrine tumors without invasive component, or benign pancreatic disease
- Patients who have received neoadjuvant chemotherapy will be included in the neoadjuvant group for the third part of the study
- Patients without neoadjuvant chemotherapy will be included in the non-neoadjuvant group for the third part of the study
You will not qualify if you...
- Presence of metastatic disease or disease preventing surgical resection
- Receipt of neoadjuvant chemotherapy or radiation within 6 months before enrollment for the first and second parts of the study
- Receipt of neoadjuvant radiation within 6 months before enrollment for the third part of the study
- INR greater than 2
- Known clotting factor deficiency or hypercoagulable state
- Need or anticipated need for full anticoagulation during hospitalization for surgery
- Use of antiplatelet agents other than aspirin within one week before surgery
- IPMN or pancreatic neuroendocrine tumors suspected to have invasive components by imaging
- If blood collection during surgery would cause undue risk as determined by the surgeon
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
W
William Jarnagin, MD
CONTACT
P
Peter Kingham, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here